Stan Berenshteyn's Stock Ratings

Wells Fargo Analyst

Stan Berenshteyn is an analyst at Wells Fargo. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/17/2024

Overall Average Return

-5.26%

Smart Score

49.2%

Overall Average Return Percentile

26th

Number of Ratings

45
Buy NowGet Alert
05/10/2024HCATBuy Now
Health Catalyst
$6.9288%$14 ā†’ $13MaintainsOverweightGet Alert
04/30/2024ACCDBuy Now
Accolade
$7.6830.21%$12 ā†’ $10MaintainsEqual-WeightGet Alert
03/25/2024GDRXBuy Now
GoodRx Holdings
$7.1440.06% ā†’ $10UpgradeEqual-Weight ā†’ OverweightGet Alert
03/01/2024GDRXBuy Now
GoodRx Holdings
$7.145.04%$6 ā†’ $7.5MaintainsEqual-WeightGet Alert
02/09/2024OMCLBuy Now
Omnicell
$30.73-15.39%$28 ā†’ $26MaintainsEqual-WeightGet Alert
02/09/2024DOCSBuy Now
Doximity
$28.86-6.44%$25 ā†’ $27MaintainsEqual-WeightGet Alert
01/09/2024ACCDBuy Now
Accolade
$7.6856.25%$10 ā†’ $12MaintainsEqual-WeightGet Alert
12/06/2023HQYBuy Now
HealthEquity
$82.7812.35%$89 ā†’ $93MaintainsOverweightGet Alert
11/03/2023OMCLBuy Now
Omnicell
$30.73-8.88%$39 ā†’ $28UpgradeUnderweight ā†’ Equal-WeightGet Alert
10/25/2023VEEVBuy Now
Veeva Sys
$209.969.07%$211 ā†’ $229UpgradeEqual-Weight ā†’ OverweightGet Alert
09/26/2023OMCLBuy Now
Omnicell
$30.7326.91%$56 ā†’ $39MaintainsUnderweightGet Alert
09/05/2023VEEVBuy Now
Veeva Sys
$209.960.5%$180 ā†’ $211MaintainsEqual-WeightGet Alert
08/11/2023DOCSBuy Now
Doximity
$28.86-13.37%$37 ā†’ $25MaintainsEqual-WeightGet Alert
08/10/2023GDRXBuy Now
GoodRx Holdings
$7.14-1.96%$6 ā†’ $7MaintainsEqual-WeightGet Alert
07/20/2023OMCLBuy Now
Omnicell
$30.7382.23%$65 ā†’ $56DowngradeOverweight ā†’ UnderweightGet Alert
06/30/2023ACCDBuy Now
Accolade
$7.6882.29%$13 ā†’ $14MaintainsEqual-WeightGet Alert
05/01/2023DOCSBuy Now
Doximity
$28.8628.21%$39 ā†’ $37DowngradeOverweight ā†’ Equal-WeightGet Alert
04/21/2023ACCDBuy Now
Accolade
$7.6869.27%$10 ā†’ $13MaintainsEqual-WeightGet Alert
04/04/2023HCATBuy Now
Health Catalyst
$6.92131.38%$13 ā†’ $16UpgradeEqual-Weight ā†’ OverweightGet Alert
03/07/2023HCATBuy Now
Health Catalyst
$6.9288%$11 ā†’ $13MaintainsEqual-WeightGet Alert
03/06/2023TDOCBuy Now
Teladoc Health
$12.2188.37%$28 ā†’ $23MaintainsEqual-WeightGet Alert
03/02/2023GDRXBuy Now
GoodRx Holdings
$7.14-15.97%$5.5 ā†’ $6MaintainsEqual-WeightGet Alert
02/10/2023DOCSBuy Now
Doximity
$28.8635.14%$44 ā†’ $39MaintainsOverweightGet Alert
02/03/2023HQYBuy Now
HealthEquity
$82.787.51%$101 ā†’ $89MaintainsOverweightGet Alert
01/24/2023OMCLBuy Now
Omnicell
$30.73111.52%$71 ā†’ $65MaintainsOverweightGet Alert
12/07/2022HQYBuy Now
HealthEquity
$82.7822.01%$104 ā†’ $101MaintainsOverweightGet Alert
11/11/2022DOCSBuy Now
Doximity
$28.8652.46%$38 ā†’ $44MaintainsOverweightGet Alert
11/04/2022OMCLBuy Now
Omnicell
$30.73131.04%$158 ā†’ $71MaintainsOverweightGet Alert
10/31/2022VEEVBuy Now
Veeva Sys
$209.96-14.27% ā†’ $180Initiates ā†’ Equal-WeightGet Alert
10/31/2022HCATBuy Now
Health Catalyst
$6.9244.61% ā†’ $10Initiates ā†’ Equal-WeightGet Alert

Recent Analyst Stock Rating News

Forecasting The Future: 13 Analyst Projections For GoodRx Holdings
6 Analysts Assess Doximity: What You Need To Know
6 Analysts Assess Doximity: What You Need To Know
The Latest Analyst Ratings For GoodRx Holdings
Esperion Therapeutics, Masimo And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling by around 50 points on Monday. Shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) rose sharply inĀ todayā€™s pre-market trading.
What 6 Analyst Ratings Have To Say About Doximity
Accolade Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Forecasting The Future: 5 Analyst Projections For Doximity
What's Going With Medical Professionals-Networking Service Doximity Stock Today?
Doximity exceeds Q3 2024 expectations with $135.3 million revenue, up 17% YoY. CEO Jeff Tangney highlights double-digit growth, beating adjusted EPS and raising FY2024 outlook.
A Glimpse Into The Expert Outlook On Accolade Through 7 Analysts
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free